

**MAY 05 2004**

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

**Complete if Known**

Application Number	10/622,492
Filing Date	July 21, 2003
First Named Inventor	Karen Jackson
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	330499-00009

Sheet	1	of	3
-------	---	----	---

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	†*
		Country Code <sup>3</sup> * Number <sup>4</sup> * Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			
h		WO99/18967	04-22-1999	Therapeutics Limited		
h		EP 0 517 412	12-09-1992	Merck Sharp & D		
h		EP 0 434 364	06-26-1991	Merk & Co Inc.		

Examiner Signature	<i>N. Look</i>	Date Considered	9/19/05
-----------------------	----------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/622,492
		Filing Date	July 21, 2003
		First Named Inventor	Karen Jackson
		Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Sheet 2 of 3	Attorney Docket Number	330499-00009	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>h</i>		L. BUENO, Involvement of brain CCK in the adaptation of gut motility to digestive status and stress: A review, J Physiology (1993) vol. 87, pp. 301-306	
<i>h</i>		J. FIORAMONTI, et al., Involvement of a CCK-dependent capsaicin-sensitive afferent pathway in the inhibitory effect of pinaverium bromide on the colonic motor response to eating in rats, Fundam Clin Pharmacol 1997;11:231-236	
<i>h</i>		C. BEGLINGER, Effect of Cholecystokinin on Gastric Motility in Humans, Annals New York Academy of Sciences, Vol 713, Issue 1, pp. 219-225, 1992	
<i>h</i>		M. D'AMATO, et al., Cholecystokinin-A receptor antagonists: therapies for gastrointestinal disorders, Exp. Opin. Invest. Drugs (1997) 6(7) pp. 819-836	
<i>h</i>		J.G. WETTSTEIN, et al., CCK Antagonists: Pharmacology And Therapeutic Interest, Pharmac. Ther., (1994), vol 62, pp. 267-282	
<i>h</i>		WILLIAMS, CYNTHIA et al., Cholecystokinin-induced antinociception is not blocked by CCK-A or CCK-B receptor antagonists, Peptides(Terrytown), 18(3) 1997 pp.409-414	
<i>h</i>		SINGH, L. et al., Modulation of the in vivo actions of morphine by the mixed CCKA/B receptor antagonist PD 142898, European Journal of Pharmacology, Amsterdam, NL, 307(3) 1996, pp. 283-289	
<i>h</i>		C.T. DOURISH et al., The Cholecystokinin Receptor Antagonist Devazepide Enhances Morphine-Induced Respiratory Depression in the Squirrel Monkey, The Journal of Pharmacology and Experimental Therapeutics, vol. 255, No. 3, 1990, pp. 1158-1164	
<i>h</i>		JOEL HARDMAN et al., Goodman & Gilman's The Pharmacological basis of Therapeutics, 9th Edition, 1996, pp. 526-529 and 540-545	

Examiner Signature	<i>h Cook</i>	Date Considered	9/19/05
--------------------	---------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/622,492
		Filing Date	July 21, 2003
		First Named Inventor	Karen Jackson
		Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Sheet 3	of 3	Attorney Docket Number	330499-00009

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
n		SHIPTON, South African J. Anesthesiology & Analgesia, Vol 6, #2, pp. 1-12, 2000	
n		CHANG et al., Proc. Natl. acad. Sci. USA, Vol. 83, pp. 4923-26, 1986	

Examiner Signature	<i>[Signature]</i>	Date Considered	9/19/05
--------------------	--------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.